IFN-alpha-2b vs Pidotimod
Head-to-head comparison of IFN-alpha-2b (Recombinant human interferon alfa-2b) and Pidotimod (3-L-Pyroglutamyl-L-Thiazolidine-4-Carboxylic Acid) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | IFN-alpha-2b | Pidotimod |
|---|---|---|
| Category | Immune Support | Immune Support |
| Full Name | Recombinant human interferon alfa-2b | 3-L-Pyroglutamyl-L-Thiazolidine-4-Carboxylic Acid |
| Molecular Weight | ~19,300 Da | 244.27 Da |
| Half-Life | 2-8 hours | 3-4 h |
| Amino Acids | 165 | 2 |
| Typical Dose | 3-10 million IU | 400-800 mg/day |
| Route | Subcutaneous/Intramuscular | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 2000 | 200 |
| Research Status | Clinical | Clinical |
IFN-alpha-2b Benefits
- ✓broad antiviral signaling
- ✓innate immune activation
- ✓reduced viral replication
- ✓clinical immunomodulation
Pidotimod Benefits
- ✓oral-immune-support
- ✓respiratory-infection-adjunct
- ✓innate-immunity
- ✓adaptive-immunity-support
IFN-alpha-2b Dosing
3-10 million IU per dose|Subcutaneous or intramuscular administration|Monitor CBC, liver enzymes, and mood
Pidotimod Dosing
400 mg PO BID|typically 15-30 days|repeated seasonal cycles in studies
IFN-alpha-2b Side Effects
- ⚠flu-like symptoms
- ⚠depression or mood changes
- ⚠cytopenias
Pidotimod Side Effects
- ⚠nausea
- ⚠diarrhea
- ⚠rash
Research Overview
IFN-alpha-2b
Extensively studied recombinant type I interferon with direct antiviral and immunoregulatory effects. Clinical literature spans hepatitis treatment, antiviral research, and immune-oncology contexts.
Pidotimod
Pidotimod has human data in recurrent infections, especially where immune stimulation or reduced infection frequency is the target. Published work commonly reports improvements in phagocyte function, mucosal defense, and fewer respiratory infection episodes.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.